Who are BAT1806's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IBI362, BAT1406, BAT1706, SHR-A1904, IBI354, IBI343.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bat1806.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BAT1806 — Competitive Intelligence Brief

BAT1806 (BAT1806) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody; PD-1/TGF-β inhibitor. Area: Oncology.

phase 3 Bispecific antibody; PD-1/TGF-β inhibitor PD-1 and TGF-β Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BAT1806 (BAT1806) — Bio-Thera Solutions. BAT1806 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BAT1806 TARGET	BAT1806	Bio-Thera Solutions	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
IBI362	IBI362	Innovent Biologics (Suzhou) Co. Ltd.	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
BAT1406	BAT1406	Bio-Thera Solutions	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
BAT1706	BAT1706	Bio-Thera Solutions	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
SHR-A1904	SHR-A1904	Shanghai Hengrui Pharmaceutical Co., Ltd.	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
IBI354	IBI354	Innovent Biologics (Suzhou) Co. Ltd.	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
IBI343	IBI343	Innovent Biologics (Suzhou) Co. Ltd.	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody; PD-1/TGF-β inhibitor class)

Bio-Thera Solutions · 3 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 3 drugs in this class
Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
Shanghai Hengrui Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BAT1806 — Competitive Intelligence Brief. https://druglandscape.com/ci/bat1806. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab